Despite a wide range of therapeutics reported in LM, there is currently a lack of consensus on the optimal therapy. LM needs prolonged monitoring as the disease could have very long periods of quiescence followed by reactivation. Pub Med Br J Dermatol. 2013 Sep 6. (Also see: Localized Scleroderma)
This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.